# Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia

> **NCT07652866** · NA · NOT_YET_RECRUITING · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 60 (estimated)

## Conditions studied

- Schizophrenia Disorder

## Interventions

- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** Sulforaphane

## Key facts

- **NCT ID:** NCT07652866
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-02
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652866, "Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*